

## Virginia Department of Health Botulism: Overview for Healthcare Providers

Organism	Clostridium botulinum, a gram positive, anaerobic, spore-forming bacterium can produce
	botulinum neurotoxin (BoNT). The toxin's effects lead to botulism. Strains of C. baratii, C.
	butyricum, and C. argentinense can also produce BoNT.
	• 7 types of toxins (types A through G) and several mosaic toxins (C/D, D/C, and A/F) have been
	recognized. Human disease is caused primarily by toxin types A, B, E, and, rarely, F.
<b>Reporting to Public</b>	Suspected or confirmed cases require <b>immediate</b> notification to the local health department (LHD).
Health	See <a href="https://www.vdh.virginia.gov/health-department-locator/">https://www.vdh.virginia.gov/health-department-locator/</a>
Infectious Dose	A few nanograms of toxin
Occurrence	<ul> <li>Botulism occurs worldwide, but the incidence is low</li> </ul>
	• In the United States, ~100–200 cases are reported annually; in Virginia, ~3 cases are reported
	annually. Most reported cases are infant botulism.
Natural Reservoir	C. botulinum spores are ubiquitous in the environment. Spores can be found in soil, dust, marine
	sediments, and the intestinal tracts of animals, including fish.
Route of Infection	Multiple types of botulism based on the route: foodborne, infant, wound, adult intestinal toxemia
	(also known as adult intestinal colonization), iatrogenic, and inhalational
	• Unintentional exposure can occur by ingesting pre-formed toxin (foodborne), ingesting spores
	(infant; adult intestinal toxemia), having a wound contaminated with spores (wound), receiving
	excess injectable toxin during cosmetic or medical procedure (iatrogenic), inhaling toxin released in
	aerosols (inhalational)
	• If BoNT was used during a bioterrorism event, it might be released in toxin-contaminated food or
	water or via aerosols
Communicability	Botulism is not transmissible from person to person, except in cases of infant botulism where it may
	be passed from stool to open wounds or cuts
Risk Factors	All persons are susceptible
	• Foodborne: consuming homemade foods that are improperly canned, preserved, or fermented or
	consuming certain kinds of homemade alcohol (e.g., prison wine known as "pruno" or "hooch")
	• Infant (<12 months of age): consuming honey or products made with honey
	<ul> <li>Wound: injecting certain drugs (e.g., black tar heroin) or having contamination of a wound or open fracture with soil or gravel</li> </ul>
	<ul> <li>Adult intestinal toxemia: risk is higher among those with a weakened immune system, altered GI</li> </ul>
	anatomy or altered gut bacterial flora because of antimicrobial use
	Iatrogenic: receiving excess injectable botulinum toxin for cosmetic or medical procedures
	<ul> <li>Inhalational: exposure to toxins in aerosols (e.g., laboratory exposure)</li> </ul>
Case-fatality Rate	Case-fatality rate among those with appropriate treatment is approximately 5%
Incubation Period	• Foodborne: 12–72 hours (range 2 hours–8 days)
	Infant and adult intestinal toxemia: unknown
	• Wound: approximately 7 days (range 4–14 days)
	• latrogenic: days to weeks
	• Inhalational: approximately 1–3 days
<b>Clinical Description</b>	Classic presentation: Symmetrical cranial nerve paresis is initial finding resulting in visual
	disturbance, dysarthria, and dysphagia. Patients are afebrile and mentally alert.
	• Subsequent neurological findings: A symmetric, descending, flaccid paralysis, extending to trunk
	and limbs. This may lead to respiratory failure and require mechanical ventilation.

	Patients may have GI symptoms (abdominal pain, distended abdomen, or constipation)
	• Infants with botulism appear lethargic, feed poorly, are constipated, and have a weak cry and poor
	muscle tone; infants might resemble "failure to thrive" or "floppy baby"
Differential	• For adults: Guillain-Barré syndrome, myasthenia gravis, cerebrovascular accident, bacterial or
Diagnosis	chemical food poisoning, tick paralysis, chemical intoxication (e.g., carbon monoxide), mushroom
	poisoning, poliomyelitis, and psychiatric illness
	• For infants: sepsis, meningitis, acute flaccid myelitis, electrolyte imbalance, Reye's syndrome,
	congenital myopathy
	• NOTE: It has been reported that botulism may be misdiagnosed as Guillain-Barre syndrome, stroke,
	myasthenia gravis, etc. Consider botulism in any patient with generalized weakness, particularly in
	association with evidence of cranial nerve paresis.
Radiography	Infant botulism might reveal dilated colonic loops by radiography
Specimen	• Acceptable specimens to test for botulinum toxin include: stool (5–10 g) or sterile enema (10–20
Collection and	mL), serum (2–4mL), gastric aspirate or vomitus (10–20 mL), tissue or exudate (1 g), suspected food
Laboratory Testing	samples (if available). Stool (or sterile enema) and serum are typically the specimens of choice. For
	infant cases, the Division of Consolidated Laboratory Services (DCLS) will accept 1–2mL of serum to
	perform limited testing if appropriate volume cannot be collected.
	• If botulism is suspected, notify the <u>LHD</u> immediately to discuss the case and laboratory testing.
	Specimens may be sent to DCLS after VDH has approved testing.
	• For questions about specimen collection, contact the DCLS Emergency Duty Officer available 24/7
	at 804-335-4617
Treatment	Botulinum antitoxin and supportive care, including respiratory and nutritional support
	• Treatment with botulinum antitoxin heptavalent (known as <u>BAT</u> ) should be based on the clinical
	presentation and findings. Treatment should NOT be delayed by waiting for confirmatory test
	results. Goal is to give antitoxin as early as possible (ideally less than 24 hours after symptoms
	begin). Antitoxin typically prevents paralysis from worsening.
	• BAT is available only from the Strategic National Stockpile (SNS) after consultation with LHD and
	CDC (available 24/7 at 770-488-7100)
	• Infant botulism is treated as soon as possible after clinical diagnosis with intravenous, human-
	derived botulism immune globulin ( <u>BabyBIG®</u> ). BabyBIG® is available only from California
	Department of Public Health's Infant Botulism Treatment and Prevention Program (available 24/7
	at 510-231-7600) after consultation. In a bioterrorism attack, BabyBIG <sup>®</sup> is not recommended.
	• For more information, including dosing instructions, consult the <u>BAT</u> and <u>BabyBIG</u> package inserts
	or call the Virginia Department of Health Emergency Consultant Pharmacist at 804-786-4326
Postexposure Prophylaxis	None. Antitoxins are not useful for preventive purposes.
Vaccine	Currently, there is no FDA-licensed vaccine against botulism
Infection Control	<ul> <li>Use Standard Precautions; patients do not need to be isolated</li> </ul>
	• Those known to have eaten tainted food should be kept under close medical observation. If the
	person begins to develop symptoms or signs of botulism, botulinum antitoxin should be given
	promptly, and the patient kept under close medical observation.
	• Infants with botulism can shed <i>C. botulinum</i> and toxin in the stool for weeks to months after onset.
	Hand hygiene among care givers is critical. Diapers should be disposed of so that other people or
	animals cannot come into contact with them. People with open cuts or wounds on their hands
	should wear gloves when handling soiled diapers. Avoid close contact with other infants (e.g.,
	sharing crib and toys) while excretion might occur.
ackage Inserts	

Package Inserts

BAT: <u>https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/bat-botulism-antitoxin-heptavalent-b-c-d-e-f-g-equine</u> BabyBIG: <u>https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/babybig</u>